AbbVie News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

14.01.22	U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis (PR Newswire)
11.01.22	AbbVie Confirms Outlook Of Over $15 Bln In Combined Risk-Adj. Sales For Rinvoq, Skyrizi In 2025 (RTTNews)
11.01.22	AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025 (PR Newswire)
11.01.22	ACELYRIN Appoints Melanie Gloria as Chief Operating Officer (PR Newswire)
07.01.22	AbbVie Submits Applications For Upadacitinib In Non-Radiographic Axial Spondyloarthritis To FDA (RTTNews)
07.01.22	AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) (PR Newswire)
04.01.22	AbbVie: Teliso-V Gets Breakthrough Therapy Designation (RTTNews)
04.01.22	AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer (PR Newswire)
23.12.21	Top 10 Blockbuster Drugs In 2021 (RTTNews)
16.12.21	Allergan Aesthetics Completes Acquisition of Soliton (PR Newswire)
15.12.21	FDA Approves AbbVie's RINVOQ To Treat Active Psoriatic Arthritis (RTTNews)
15.12.21	RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis (PR Newswire)
14.12.21	Genentech's Polivy Combination Reduces Risk Of Disease Worsening Or Death By 27% In DLBCL (RTTNews)
13.12.21	AstraZeneca Elated On Calquence Data, IMGN's IMGN632 Appears To Be Promising In AML, XRTX On Watch (RTTNews)
09.12.21	Allergan Announces Availability Of FDA-Approved Eye Drop VUITY - Quick Facts (RTTNews)
09.12.21	VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available (PR Newswire)
06.12.21	AbbVie's Upadacitinib Achieves Primary & Secondary Endpoints In Phase 3 Study On Crohn's Disease (RTTNews)
06.12.21	Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease (PR Newswire)
03.12.21	AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S. (PR Newswire)
30.11.21	AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA) (PR Newswire)
19.11.21	Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting (PR Newswire)
18.11.21	New Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission (PR Newswire)
18.11.21	AbbVie Brings VENCLEXTA Plus Obinutuzumab To Chronic Lymphocytic Leukemia Patients In Quebec (RTTNews)
17.11.21	AbbVie: SKYRIZI Gets EU Approval To Treat Adults With Active Psoriatic Arthritis (RTTNews)
17.11.21	AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis (PR Newswire)
15.11.21	Allergan Aesthetics Celebrates Third Annual BOTOX® Cosmetic (onabotulinumtoxina) Day (PR Newswire)
10.11.21	AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025 (PR Newswire)
09.11.21	AbbVie Presents Positive Data On Upadacitinib In Active Psoriatic Arthritis And Axial Involvement (RTTNews)
09.11.21	AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021 (PR Newswire)
09.11.21	AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis (PR Newswire)
08.11.21	Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting (PR Newswire)
05.11.21	AbbVie Says Phase 3 Data On Risankizumab Shows Greater Improvements In Psoriatic Arthritis Signs (RTTNews)
05.11.21	AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021 (PR Newswire)
04.11.21	AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting (PR Newswire)
01.11.21	AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021 (PR Newswire)
30.10.21	FDA Approves Allergan's VUITY As First Eye Drop To Treat Presbyopia (RTTNews)
29.10.21	U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision) (PR Newswire)
29.10.21	AbbVie Says Cariprazine Met Primary Endpoint In Phase 3 Study For Major Depressive Disorder (RTTNews)
29.10.21	AbbVie Raises FY21 Outlook; Boosts Dividend 8.5% - Quick Facts (RTTNews)
29.10.21	AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder (PR Newswire)
29.10.21	AbbVie Q3 adjusted earnings Beat Estimates (RTTNews)
29.10.21	AbbVie Reports Third-Quarter 2021 Financial Results (PR Newswire)
28.10.21	AbbVie: Phase 3 Trial Of ABBV-951 Shows Improvement In Motor Fluctuations In Parkinson's Disease (RTTNews)
28.10.21	AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with A... (PR Newswire)
26.10.21	Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia (PR Newswire)
19.10.21	FDA OKs Cyltezo As First Interchangeable Biosimilar To Humira (RTTNews)
15.10.21	AbbVie's Risankizumab Gets CHMP Positive Opinion For Active Psoriatic Arthritis Treatment (RTTNews)
15.10.21	AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) (PR Newswire)
11.10.21	Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness (PR Newswire)
07.10.21	AbbVie: RINVOQ Meets Primary Endpoints In Phase 3 Studies - Quick Facts (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

mehr

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester